Kornimate/medical-research-clean huggingface dataset:
high performance computing of personalized cardio component models

Conditions: Coronary Artery Disease

Summary: the objective of the heart study is to develop a multiscale model of the coronary circulation based on multimodal imaging data (angiography, echocardiography). the predictive comprehensive multi-scale model, developed during this proof-of-concept study, will be used for analyzing functional aspects of coronary artery disease. model validation is performed against invasive measurements

the main objective of heart is the development and validation of a patient-specific multiscale computational model of the coronary circulation with high predictive power in healthy and diseased vessels: * comprehensive modeling of the anatomical and hemodynamic phenomena in the coronary circulation based on input data acquired from both angiography and echocardiography; * assessment of functional parameters and subsequent validation of the models; * high performance computing architecture for efficiently addressing the multi-scale complexity, which is a critical requirement for translation into clinical decision making. patient measurements used as input data for the multiscale models, or for validating the computational results include: * angiography: targeted angiographic views include lao 30, lao 30/20 cranial, lao 30/20 caudal, rao 30 (rca views) and rao 25/25 caudal, rao 0/40 caudal, rao 10/40 cranial, lao 50/20 cranial, lao 50/20 caudal (lca views) * echocardiography: * standard apical acquisitions (2d harmonic 4-chamber, 2-chamber, 3-chamber) * color flow doppler/spectral doppler (mr, ai, tr evaluation; cw and pw spectral doppler) * three-dimensional imaging (from apical 4-chamber view one ecg-triggered real time complete full volume acquisition including lv and la - 1 acquisition at low volume per second (vps) rate and one at high vps, real time volumetric color flow doppler, cover mv and av). * non-invasive pressure measurements: cuff-based measurements at the left and right arm, before echocardiography and angiography * invasive pressure measurements: rest - aortic pressure (pa), distal pressure (pd), pd/pa ratio; hyperemia - aortic pressure (pa), distal pressure (pd), ffr (pd/pa)

Eligibility criteria:
inclusion criteria: * age \>18 years * providing written informed consent * scheduled to undergo clinically-indicated non-emergent invasive coronary angiography (ica) * likelihood of stenosis in one of the main coronary epicardial vessels (lad, lcx, rca) exclusion criteria: * prior pci * prior bypass surgery * prior valve surgery or replacement * significant arrhythmia * very low systolic bp (\<90 mmhg) * abnormally high hr (\>120 bpm) * significant left main disease * stemi or nstemi * suspected microvascular disease

Keywords: coronary artery disease ffr diagnosis computational model non-invasive
evaluating accuracy of breath sound recordings and stop-bang screening for obstructive sleep apnea while awake

Conditions: Sleep Apnea, Obstructive

Summary: the investigators will perform a diagnostic accuracy study comparing tracheal breath sound recordings in awake individuals to the stop-bang screening questionnaire, using the apnea-hypopnea index (ahi) score determined by polysomnography as the gold standard.

obstructive sleep apnea (osa) is a breathing disorder with numerous health effects including a greater risk of peri-operative anesthetic complications. numerous screening tools exist but are not without limitations. diagnostic overnight sleep studies are resource-intensive and difficult to obtain in the short time period between pre-operative clinic assessment and the day of surgery. this project aims to test the diagnostic performance of a new screening technology, awake-osa, for screening of obstructive sleep apnea (osa). "awake-osa" uses a small external microphone placed on the neck, to record and analyze tracheal breath sounds at the bedside while the patient is awake. using polysomnography (psg) as a gold standard, the investigators will compare awake-osa (breath sound recording) and the stop-bang screening questionnaire in their ability to accurately identify patients with osa, as well as classify osa in terms of severity. early, point-of-care diagnosis has the potential to provide a low-cost, convenient alternative to traditional screening questionnaires and enable more selective use of psg. our goal is to improve peri-operative patient safety while improving use of resources and streamlining patient care.

Eligibility criteria:
inclusion criteria: * 18 years and older. * referred for diagnostic sleep study. * willing and able to consent. exclusion criteria: * under the age of 18 yrs. * unwilling or unable to give consent. * expected to have an abnormal eeg (epilepsy, brain tumour, deep brain stimulator). * significant craniofacial abnormality (ex. unrepaired cleft lip/palate).
effects of hepatic ultrasound on metabolic homeostasis

Conditions: Healthy; Insulin Resistance

Summary: the purpose of this study is to define the effect of ultrasound exposure of the liver in the region of the porta hepatis on glucose homeostasis and insulin resistance in healthy subjects.


Eligibility criteria:
inclusion criteria: * 18 - 60 years of age * aim 1: healthy lean men and women, bmi\<24 kg/m2, with normal fasting glucose (blood glucose between 60 and 100mg/dl and normal glucose tolerance on ogtt (blood glucose \<140 mg/dl at 2 hours post glucose challenge) at the screening visit. * aim 2: overweight and obese men and women, bmi 25 - 35 kg/m2 exclusion criteria: * type 1 and type 2 diabetes * surgery in the past 90 days * previous surgery of the spleen or splenectomy, esophagus, lungs, stomach, duodenum, or liver * recent traumatic injury, including intra-cerebral hemorrhage and visceral injury * end stage renal disease and/or uremia * active malignancy * previous leukemia and/or lymphoma * human immunodeficiency virus infection or aids * rheumatoid arthritis or other immune-mediated diseases (e.g. inflammatory bowel disease) * arrhythmias, including but not limited to, atrial fibrillation, atrial flutter, bradycardia, ventricular arrhythmias, and a-v block * implanted pacemaker or cardioverter/defibrillator (aicd) * history of stable or unstable angina, myocardial infarction, angioplasty or coronary arterial by-pass grafting surgery * history of stroke or tia * history of deep venous thrombosis (dvt) and/or pulmonary embolism (pe) * previous episodes of pancreatitis * spinal disorders * chronic pain syndromes * history of thrombosis or bleeding disorders * stage iii-iv pressure ulcers * sickle cell anemia or other anemia syndromes * monocytosis * thrombocytopenia * diagnosed with fever of unknown origin (fuo) * previously or currently implanted vagus nerve stimulator * previously or currently implanted spinal cord stimulator * other chronically-implanted electronic medical device * history of seizures * history of cancer * individuals who have taken any of the following medications within two weeks of receiving ultrasound delivery: anti-coagulant, anti-platelet, anti-inflammatory, immunosuppressive agents, alpha and/or beta adrenoceptor blocking agents, anti-seizure medications, anti-diabetic medication * individuals with a substance abuse problem * pregnant women * ascites detected in the abdomen that may effect delivery of shear wave elastroghapy pulse
a study to evaluate symlin in adolescent subjects with type 1 diabetes mellitus

Conditions: Type 1 Diabetes Mellitus

Summary: this study will be the first evaluation of symlin in adolescent subjects with type 1 diabetes mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and physiological effects (pharmacodynamics), and safety and tolerability of symlin in these subjects.


Eligibility criteria:
inclusion criteria: * diagnosed with type 1 diabetes mellitus for at least 1 year prior to screening * be on a stable regimen requiring multiple daily injections of basal and mealtime insulin or continuous subcutaneous insulin infusion for at least 2 weeks prior to screening * hba1c between 6.0% and 10.0%, inclusive, at screening * body weight \>=50 kg at screening exclusion criteria: * currently being treated with the following medications: \*any oral antihyperglycemic agent; \*drugs that directly affect gastrointestinal motility * has been previously treated with symlin/pramlintide (or has participated in a symlin/pramlintide clinical study) * has received any investigational drug within 1 month of screening

Keywords: type 1 diabetes pediatric pramlintide symlin amylin
hemodynamic comparison of peripheral and central va ecmo.

Conditions: Shock, Cardiogenic; Cardiac Arrest; Extracorporeal Circulation; Complications; Hemodynamics Instability

Summary: the goal of this clinical trial is to monitor hemodynamic differences between central veno-arterial extracorporeal membrane oxygenation (va ecmo) and peripheral va ecmo. the main question it aims to answer is: * efficacy of the different cannulation strategies for the establishment of for va-ecmo circulation on hemodynamics and organ perfusion. participants require va ecmo support, will be divided into two groups in an intention-to-treat analysis: central artery cannulation and peripheral artery cannulation. researchers will analyze different cannulation strategies for va-ecmo and identify potential advantages and disadvantages for two groups of va-ecmo.


Eligibility criteria:
inclusion criteria: * age≥18 years * participants with cardiogenic shock * obtaining informed consent from participants or their affiliated beneficiaries exclusion criteria: * irreversible heart failure * contraindications to anticoagulation therapy * uncontrolled bleeding * irreversible neurological pathology * participants limited to extracorporeal cardiopulmonary resuscitation
speech intelligibility in quiet and noise for new vs. legacy hearing aids

Conditions: Hearing Loss, Sensorineural; Hearing Loss

Summary: this clinical investigation is designed to compare audiological performance (i.e., measurements of sound quality and speech understanding) between starkey's new receiver-in-canal device and a commercially available legacy receiver-in-canal device.

starkey is investigating a new hearing aid with several new audiological features. these features have been assessed for benefit, individually, but this clinical investigation will serve as a test for safety and efficacy with all hearing aid features, together. the design of this study is a single-blinded, crossover design and will be conducted at starkey's headquarters in eden prairie, mn.

Eligibility criteria:
inclusion criteria: * adults, minimum age of 18 * native english speakers * ability to complete questionnaires and laboratory assessments * symmetric, mild to moderately-severe sensorineural hearing loss * informed consent completed with signature exclusion criteria: * inability to visit the starkey headquarters building for testing * central or middle ear hearing problems * medical contraindications to wearing hearing aids * learning disability, major cognitive handicap, or serious neurological or psychiatric disease that would prevent or restrict participation, as determined by the pi or designee
inhaled treprostinil in participants with pulmonary hypertension due to chronic obstructive pulmonary disease (ph-copd)

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease

Summary: this open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed study rin-ph-304 (nct03496623). this study hypothesizes that long-term safety findings will be similar to those observed in the randomized, placebo-controlled, double-blind, adaptive study 'a phase 3, randomized, placebo-controlled, double-blind, adaptive study to evaluate the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (ph-copd)(rin-ph-304).

this is a multi-center, open-label study for eligible participants who completed all scheduled study visits during the treatment period of study rin-ph-304. participants who provide informed consent for this open-label extension study on or prior to the final study visit of rin-ph-304 may participate in the study, provided all other eligibility criteria are met. the rin-ph-304 final study visit and the rin-ph-305 enrollment visit will occur on the same day. all participants will reinitiate inhaled treprostinil at 3 breathes (18 micrograms \[mcg\]) 4 times daily (qid) during waking hours. study drug doses should be maximized to tolerability throughout the study, and dose titrations should occur as rapidly as possible (as directed by the investigator) with a target dosing regimen of 15 breaths qid or the maximum tolerated dose.

Eligibility criteria:
inclusion criteria: 1. participant voluntarily gives informed consent to participate in the study. 2. participant completed study rin-ph-304. 3. women of childbearing potential (defined as less than 1 year post-menopausal and not surgically sterile) must agree to practice abstinence or use 2 highly effective methods of contraception (defined as a method of birth control that results in a low failure rate, \[less than 1% per year\], such as approved hormonal contraceptives, barrier methods \[such as condom or diaphragm\] used with a spermicide, or an intrauterine device) for the duration of study treatment and for 48 hours after discontinuing study drug. 4. males with a partner of childbearing potential must agree to use a barrier method (condom) with a spermicide for the duration of treatment and for at least 48 hours after discontinuing study drug. exclusion criteria: 1. the participant is pregnant or lactating. 2. the participant was prematurely discontinued from study rin-ph-304. 3. the participant is intolerant to inhaled prostanoid therapy. 4. the participant is unwilling or unable to use sponsor-provided devices (actigraph, spirometer, or smart device). 5. the participant is scheduled to receive another investigational drug, device, or therapy during the course of this study. 6. any other clinically significant illness or abnormal laboratory value(s) that, in the opinion of the investigator, might adversely affect the interpretation of the study data.

Keywords: treprostinil lung diseases hypertension vascular diseases
a prospective study to evaluate the diagnostic accuracy of computer-aided diagnosis (cadx) system in real-time characterization of colorectal neoplasia

Conditions: Colorectal Neoplasms

Summary: the investigators hypothesize that a newly developed cadx system will have a higher diagnostic accuracy in predicting histopathology of colorectal neoplasia than both expert and junior endoscopists.

accurate diagnosis and characterization of colorectal polyps is essential before endoscopic resection. optical diagnosis by enhanced imaging modality (e.g. narrow band imaging, nbi) allows real-time prediction of histopathology. it can assist endoscopists to select the appropriate technique and differentiate between neoplastic or non-neoplastic polyps. nevertheless, due to the substantial inter-observer variability, the widespread use was limited. recently, artificial intelligence and computer-aided polyp diagnosis (cadx) systems have evolved rapidly. the major limitation was the heterogeneity from different types of imaging modalities. endocytoscopic images require extra steps for pre-staining and magnification, which are time consuming and operator dependent. as a result, it limits the generalisability and applicability in real-world settings. a novel cadx system will be developed for real-time histopathological prediction of colorectal neoplasia, by using non-magnified conventional white-light and image enhanced endoscopy (nbi). the diagnostic accuracy of this cadx system will be compared with both expert and junior endoscopists.

Eligibility criteria:
inclusion criteria: 1. they have received colonoscopy for screening, surveillance or symptom investigation; 2. they have endoscopic images and videos captured and stored during colonoscopy which are available to be retrieved; 3. they have histologically proven colorectal neoplasia. 4. written consent obtained exclusion criteria: 1. poor quality endoscopic images and videos defined as: 1. incomplete visualization of the colorectal neoplasia due to technical reasons (e.g. out-of-focus, motion-blurred or insufficient illumination); 2. artifacts due to mucus, air bubbles, stool, or blood. 2. active gastrointestinal bleeding; 3. fulminant colitis; 4. obscured view due to poor bowel preparation; 5. artificial staining of lesion due to chromoendoscopy. 6. unable to obtain informed consent
effect of lidocaine and adrenaline soaked gauze versus normal saline soaked at skin graft donor site of thigh

Conditions: Non-healing Wound

Summary: investigator is studying the effects of lidocaine and adrenaline soaked gauze vs normal saline soaked gauze at skin graft donor site of thigh. haemostatic effect, epithelization and post operative pain will be assessed on follow up.

after admission participants will be randomized either to be in group a or group b. closed envelop technique will be used for random assignment of the patients. group a will be receiving 2% lidocaine and 1:100,000 adrenaline soaked gauze while group b will be given only normal saline soaked gauze at donor-site for ten minutes. the primary end point of study is intraoperative bleeding. the secondary end points of study include no. of dressings required in first 24 hours after surgery, donor site epithelization at 14th post-operative day, post-operative pain in first 24 hours after surgery along with systemic analgesia requirement after surgery.

Eligibility criteria:
inclusion criteria: * • patients of both the gender of age \> 15 years * multiple donor-sites exclusion criteria: bleeding disorder * concomitant injuries * donor site other than thigh * previously harvested donor-site * patients on antiplatelet medications
extracorporeal shock wave treatment - can the pain be reduced?

Conditions: Fasciitis, Plantar; Achillodynia; Periarthritis Calcarea; Epikondylopathia Humeri /Radii

Summary: patients with fascititis plantaris, achillodynie, periarthropathia humerosacpularis calcarea or epikondylopathia humeri /radii get the shock wave therapy in our clinic as planned. during our study the investigators want to ask for pain, pain reduction and function.

patients with either fascititis plantaris, achillodynie, periarthropathia humerosacpularis calcarea or epikondylopathia humeri /radii get a shock wave therapy in our clinic of rheumatology as planned. during our study the investigators ask for pain, pain reduction and function (all questionnaires).

Eligibility criteria:
inclusion criteria: -patients with: * fascititis plantaris, * achillodynie, * periarthropathia humerosacpularis calcarea or * epicondylopathia humeri /radii, who got the shock wave therapy. exclusion criteria: * anticoagulation, * sepsis
neurokinin-1 receptor antagonist for the treatment of itch in eb patients

Conditions: Epidermolysis Bullosa; Pruritus

Summary: our goal is to determine whether daily oral administration of vpd-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with epidermolysis bullosa (eb).

itch is the most common complaint reported by patients with eb of all subtypes, and there is no current effective treatment. itch often triggers scratching that creates new wounds and increases eb disease severity. this study aims to target the physiological mechanisms of pruritus (itch) in patients with eb. substance p is a major mediator of pruritus and binds to the receptor neurokinin-1 (nk1), which is expressed in the central nervous system and the skin. vpd-737 (serlopitant), a novel drug that inhibits the nk1 receptor, has been shown to reduce severe itch in a previous study of 257 adult patients with chronic pruritus. each patient will be un-blinded individually after completing 3 months of study period. all patients who complete the study will be offered a 2-month period on active drug. patient who received active drug in the first period will be contacted and asked if they would like to continue on active drug for an additional 2 months. patients who received placebo in the first period will be contacted and asked if they would like to repeat the study on open label for 2 months.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of epidermolysis bullosa (eb) and pruritus exclusion criteria: * chronic liver or renal disease
trial of motexafin gadolinium and pemetrexed (alimta®) for second line treatment in patients with non-small cell lung cancer

Conditions: Non-Small Cell Lung Carcinoma

Summary: the goals of this study are: * to determine if the combination of two drugs, motexafin gadolinium and pemetrexed, may be an effective treatment for patients with non-small cell lung cancer (nsclc) who have had one previous chemotherapy regimen that included a platinum containing drug such as cisplatin or carboplatin. * to assess response to treatment in patients with nsclc six months after beginning study treatment.


Eligibility criteria:
inclusion criteria: * 18 years or older * stage iiib, metastatic, or recurrent nsclc patients who have received one prior platinum-based chemotherapy regimen * ecog performance status score of 0 or 1 exclusion criteria: * laboratory values indicating inadequate function of bone marrow, liver, or kidneys * symptomatic or uncontrolled brain metastases * evidence of meningeal metastasis * \> 1 prior regimen (not counting adjuvant or neo-adjuvant cytotoxic chemotherapy if completed \> 12 months prior to regiment) * medical condition that would increase risk if treated with motexafin gadolinium or impair ability to complete study procedures and assessments

Keywords: non small cell lung cancer lung cancer metastatic lung cancer inoperable lung cancer advanced lung cancer large cell lung cancer adenocarcinoma, lung squamous cell carcinoma, lung squamous cell lung cancer large cell carcinoma, lung cancer of the lung carcinoma bronchogenic
effect of two osteopathic techniques on thickness of paravertebral muscles of the lumbar spine

Conditions: Low Back Pain

Summary: the objective of this randomized controlled trial is to describe the effect of two osteopathic techniques - "high velocity, low amplitude" (hvla) and muscle energy (me) - on thickness, activation, strength, pressure pain threshold (ppt) of the paravertebral muscles at the lumbar spine, as well as the peak plantar pressures immediately and after a two-day follow-up. the muscle thickness of the paravertebral muscles at the lumbar spine, namely internal oblique, external oblique and transversus abdominis can be altered after the application of 'high-velocity low-amplitude'(hvla)and 'muscle energy' (me)techniques immediately and after a two-day follow-up.


Eligibility criteria:
inclusion criteria: * at least one episode of low back pain over the last three months; confirmation of lumbar spine dysfunction by an experienced osteopath; age between 18 and 40 years; do not have performed physical stress activities over the last 24 hours; do not be physically active (physical activity for at least three times a week); fulfill the orientations to the follow-up assessment. exclusion criteria: * history of surgery, fracture or fixation on the lumbar spine and/or the pelvis; being pregnant; signs of radiculopathy; disc herniation at the lumbar spine; degenerative process at the lumbar spine; have received any kind of manipulative treatments over the past four weeks;

Keywords: low back pain spinal manipulation osteopathy muscle energy technique muscle thickness